{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:46Z","timestamp":1787009866213,"version":"build-2736575974"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review provides important updates in systemic sclerosis (SSc)-related gastrointestinal disease, with a particular focus on the diagnosis and management of dysmotility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>In the past 2 years, several studies were published that present interesting diagnostic insights into SSc and gastrointestinal dysmotility. Studies focusing on new therapies and the novel application of existing therapies, both in SSc and non-SSc-associated gastrointestinal dysmotility syndromes, demonstrate progress in the management of these challenging complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>SSc gastrointestinal disease is heterogeneous in its clinical presentation, which presents a challenge in diagnosis and management. Objective studies may help to identify patterns of gastrointestinal dysmotility and more specifically target therapy. A variety of drugs are now available or are under study in the management of gastrointestinal dysmotility, such as prucalopride, intravenous immunoglobulin, pyridostigmine, linaclotide, relamorelin, and others. These drugs may improve symptoms and quality of life in SSc gastrointestinal patients. Combination therapies are also under study. Electroacupuncture, dietary intervention (e.g. medical nutrition therapy, low FODmap diet), and medical cannibus may also play a role in alleviating patient symptoms; however, more data are needed to define the role of these interventions in SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000545","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T18:05:34Z","timestamp":1537985134000},"page":"533-540","source":"Crossref","is-referenced-by-count":27,"title":["Gastrointestinal involvement in systemic sclerosis: diagnosis and management"],"prefix":"10.1097","volume":"30","author":[{"given":"Zsuzsanna H.","family":"McMahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Hummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"issue":"(Suppl 100)","key":"R2-20230901","first-page":"74","article-title":"One decade distinct features, morbidity and mortality of scleroderma: a cross-sectional study","volume":"34","author":"Nazarinia","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/03009742.2016.1153141","article-title":"Lung and gastrointestinal complications are leading causes of death in SCORE, a multiethnic Singapore systemic sclerosis cohort","volume":"45","author":"Santosa","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"R4-20230901","first-page":"498","article-title":"Gastrointestinal manifestations associated with systemic sclerosis: results from the nationwide inpatient sample","volume":"30","author":"Alastal","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrgastro.2017.130","article-title":"Expert consensus document: advances in the physiological assessment and diagnosis of GERD","volume":"14","author":"Savarino","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12325-016-0473-8","article-title":"Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report","volume":"34","author":"Rey","year":"2017","journal-title":"Adv Ther"},{"issue":"11","key":"R8-20230901","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrgastro.2017.130","article-title":"Expert consensus document: advances in the physiological assessment and diagnosis of GERD","volume":"14","author":"Savarino","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cgh.2016.08.034","article-title":"Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life","volume":"15","author":"Crowell","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-20230901","first-page":"193","article-title":"Frequency of motor alterations detected through manometry in patients with esophageal symptoms and scleroderma","volume":"82","author":"Perez","year":"2017","journal-title":"Rev Gastroenterol Mex"},{"issue":"(Suppl 100)","key":"R11-20230901","first-page":"63","article-title":"Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with high resolution manometry","volume":"34","author":"Luciano","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.semarthrit.2017.05.005","article-title":"High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis","volume":"47","author":"Abozaid","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"e000169","DOI":"10.1136\/bmjgast-2017-000169","article-title":"Patients with symptoms of delayed gastric emptying have a high prevalence of oesophageal dysmotility, irrespective of scintigraphic evidence of gastroparesis","volume":"4","author":"Triadafilopoulos","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/kes429","article-title":"Gastrointestinal motility disorder assessment in systemic sclerosis","volume":"52","author":"Savarino","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","article-title":"Small intestinal bacterial overgrowth in systemic sclerosis","volume":"48","author":"Marie","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20230901","first-page":"S-82","article-title":"Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms","volume":"32","author":"Tauber","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s10620-017-4726-4","article-title":"A prospective evaluation of ileocecal valve dysfunction and intestinal motility derangements in small intestinal bacterial overgrowth","volume":"62","author":"Chander Roland","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semarthrit.2016.03.013","article-title":"Anal incontinence and vesico-sphincter events in systemic sclerosis: an epidemiologic bicentric cohort study","volume":"46","author":"Martin","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"(Suppl 3)","key":"R19-20230901","first-page":"iii36","article-title":"Gastrointestinal complications: the most frequent internal complications of systemic sclerosis","volume":"48","author":"Forbes","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/2050640616688129","article-title":"Prevalence of fecal incontinence in a cohort of systemic sclerosis patients within a regional referral network","volume":"5","author":"Garros","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"R21-20230901","first-page":"581","article-title":"Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues","volume":"56","author":"Richard","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","article-title":"Effectiveness of add-on therapy with domperidone vs. alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial","volume":"56","author":"Foocharoen","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13075-016-1094-y","article-title":"The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial","volume":"18","author":"Karamanolis","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R24-20230901","first-page":"S168","article-title":"Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis","volume":"33","author":"Clark","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","article-title":"Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study","volume":"19","author":"Vigone","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"R27-20230901","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semarthrit.2017.12.007","article-title":"Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis","volume":"48","author":"Ahuja","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20230901","first-page":"685","article-title":"Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities","volume":"23","author":"Mercado","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.1987.00370090075014","article-title":"Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities","volume":"147","author":"Johnson","year":"1987","journal-title":"Arch Intern Med"},{"key":"R30-20230901","first-page":"810","article-title":"Scintigraphic detection of metoclopramide esophageal stimulation in progressive systemic sclerosis","volume":"28","author":"Drane","year":"1987","journal-title":"J Nucl Med"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/2050640614560453","article-title":"Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: a pilot study","volume":"3","author":"Karamanolis","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2125.1991.tb05593.x","article-title":"The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study","volume":"31","author":"Kahan","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0016-5085(87)91020-1","article-title":"Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis","volume":"93","author":"Horowitz","year":"1987","journal-title":"Gastroenterology"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s100670200072","article-title":"Effects of cisapride on colonic transit in patients with progressive systemic sclerosis","volume":"21","author":"Wang","year":"2002","journal-title":"Clin Rheumatol"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00006231-200506000-00008","article-title":"Prokinetic therapy: what can be measured by gastric scintigraphy?","volume":"26","author":"Linke","year":"2005","journal-title":"Nucl Med Commun"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1572-0241.2002.05396.x","article-title":"Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride","volume":"97","author":"Boeckxstaens","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2012.07.109","article-title":"Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function","volume":"143","author":"Singh","year":"2012","journal-title":"Gastroenterology"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"G1206","DOI":"10.1152\/ajpgi.00286.2009","article-title":"Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells","volume":"297","author":"Singh","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/1529-0131(199907)42:7<1545::AID-ANR30>3.0.CO;2-T","article-title":"Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases","volume":"42","author":"Perlemuter","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N Engl J Med"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/nmo.12735","article-title":"Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls","volume":"28","author":"Menys","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/0003-4819-94-6-749","article-title":"Abnormal colonic motility in progressive systemic sclerosis","volume":"94","author":"Battle","year":"1981","journal-title":"Ann Intern Med"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5056\/jnm16100","article-title":"A double-blind, randomized, multicenter clinical trial investigating the efficacy and safety of esomeprazole single therapy versus mosapride and esomeprazole combined therapy in patients with esophageal reflux disease","volume":"23","author":"Lee","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"R45-20230901","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13256","article-title":"Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study","volume":"30","author":"Ashat","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R47-20230901","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bph.14096","article-title":"The novel, potent and highly selective 5-HT4 receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility","volume":"175","author":"Jeong","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R48-20230901","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nmo.13162","article-title":"Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle","volume":"30","author":"Pauwelyn","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nmo.13064","article-title":"Lefebvre RA 5-HT4 receptors facilitate cholinergic neurotransmission throughout the murine gastrointestinal tract","volume":"29","author":"Pauwelyn","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/nmo.12832","article-title":"Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study","volume":"28","author":"Miner","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4253\/wjge.v9.i11.558","article-title":"Efficacy of Prucalopride in bowel cleansing before colonoscopy: results of a pilot study","volume":"9","author":"Corleto","year":"2017","journal-title":"World J Gastrointest Endosc"},{"key":"R52-20230901","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/apt.13557","article-title":"Randomised clinical trial: prucalopride, a colonic pro-motility agent, reduces the duration of postoperative ileus after elective gastrointestinal surgery","volume":"43","author":"Gong","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R53-20230901","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/nmo.12736","article-title":"Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis","volume":"28","author":"Tack","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"R54-20230901","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/14656566.2013.795948","article-title":"Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives","volume":"14","author":"Stevens","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R55-20230901","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/13543784.2017.1373088","article-title":"Relamorelin for the treatment of gastrointestinal motility disorders","volume":"26","author":"Chedid","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"R56-20230901","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/13543784.2017.1288214","article-title":"Investigational drug therapies for the treatment of gastroparesis","volume":"26","author":"Sanger","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"R57-20230901","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.cgh.2015.04.184","article-title":"Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial","volume":"13","author":"Acosta","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R58-20230901","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-015-3876-5","article-title":"Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, controlled trial","volume":"61","author":"Acosta","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R59-20230901","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/apt.13810","article-title":"Lactose malabsorption in systemic sclerosis","volume":"44","author":"Marie","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R60-20230901","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.13928","article-title":"Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth","volume":"45","author":"Gatta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R61-20230901","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000814","article-title":"Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence","volume":"51","author":"Zhong","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"R62-20230901","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5056\/jnm17071","article-title":"Neuromodulation via interferential electrical stimulation as a novel therapy in gastrointestinal motility disorders","volume":"24","author":"Moore","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"R63-20230901","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12906-017-1826-9","article-title":"Electroacupuncture at LI11 promotes jejunal motility via the parasympathetic pathway","volume":"17","author":"Hu","year":"2017","journal-title":"BMC Complement Altern Med"},{"key":"R64-20230901","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.stemcr.2017.07.017","article-title":"Neural crest cell implantation restores enteric nervous system function and alters the gastrointestinal transcriptome in human tissue-engineered small intestine","volume":"9","author":"Schlieve","year":"2017","journal-title":"Stem Cell Rep"},{"key":"R65-20230901","article-title":"Abatacept to treat chronic intestinal pseudo-obstruction in five systemic sclerosis patients with a description of the index case","author":"Vigone","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"R66-20230901","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/jgh.13733","article-title":"Effect of prucalopride on intestinal gas tolerance in patients with functional bowel disorders and constipation","volume":"32","author":"Malagelada","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R67-20230901","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s10620-016-4147-9","article-title":"Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials","volume":"61","author":"Camilleri","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R68-20230901","article-title":"Application of pyridostigmine in pediatric gastrointestinal motility disorders: a case series","author":"Manini","year":"2017","journal-title":"Paediatr Drugs"},{"key":"R69-20230901","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1463-1318.2009.01838.x","article-title":"The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine","volume":"12","author":"O\u2019Dea","year":"2010","journal-title":"Colorectal Dis"},{"key":"R70-20230901","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1542\/peds.2017-0007","article-title":"The use of pyridostigmine in a child with chronic intestinal pseudo-obstruction","volume":"141","author":"Choudhury","year":"2018","journal-title":"Pediatrics"},{"key":"R71-20230901","first-page":"19","article-title":"Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation","volume":"7","author":"Soufi-Afshar","year":"2016","journal-title":"Caspian J Intern Med"},{"key":"R72-20230901","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10286-008-0476-x","article-title":"Pilot study of pyridostigmine in constipated patients with autonomic neuropathy","volume":"18","author":"Bharucha","year":"2008","journal-title":"Clin Auton Res"},{"key":"R73-20230901","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2006.06.018","article-title":"Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine","volume":"131","author":"Pasha","year":"2006","journal-title":"Gastroenterology"},{"key":"R74-20230901","doi-asserted-by":"crossref","first-page":"e0176673","DOI":"10.1371\/journal.pone.0176673","article-title":"Sildenafil normalizes bowel transit in preclinical models of constipation","volume":"12","author":"Sharman","year":"2017","journal-title":"PLoS One"},{"key":"R75-20230901","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MCG.0000000000000405","article-title":"The impact of pelvic floor and lower gastrointestinal symptoms on quality of life in women with systemic sclerosis","volume":"50","author":"Umar","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"R76-20230901","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/00365521.2016.1218537","article-title":"Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study","volume":"51","author":"Collins","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"R77-20230901","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cpt.568","article-title":"Medical cannabis: Another piece in the mosaic of autoimmunity?","volume":"101","author":"Katz","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R78-20230901","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MEG.0000000000000779","article-title":"Role of cannabis in digestive disorders","volume":"29","author":"Goyal","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R79-20230901","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/jcmm.13359","article-title":"Endocannabinoid-related compounds in gastrointestinal diseases","volume":"22","author":"Pesce","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R80-20230901","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0148607115597883","article-title":"Medical Nutrition Therapy for Patients With Advanced Systemic Sclerosis (MNT PASS): a pilot intervention study","volume":"41","author":"Doerfler","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:56:41Z","timestamp":1755705401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000545","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}